Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Axios on your phone

Get breaking news and scoops on the go with the Axios app.

Download for free.

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Preparing HIV vaccines in a South Africa lab for a different trial. Photo: Gallo Images/The Times/Jackie Clausen

A research team says they have developed a trial HIV vaccine that is able to neutralize dozens of strains of the virus from around the world in animals, according to a new study published in Nature Medicine Monday. The vaccine, the product of a team at the National Institutes of Allergy and Infectious Diseases (NIAID), targets a peptide in the virus' entry machinery.

Why it matters: Great strides have been made in improving the lives of those infected with the HIV virus — nearly 37 million people around the world — but researchers have been unable to develop an effective vaccine. Also, the rate of transmission remains high.

"One of the last holy grails of HIV research is the development of an HIV vaccine."
— Anthony Fauci, director, NIAID
"I would classify this as a breakthrough paper re: identifying an important new approach to an HIV vaccine. Yes, it needs additional work. Yes, it may not be the full solution. But, it induces antibodies that do not need to undergo lots of somatic hypermutation and offers a way to be a potential basic component toward the development of a neutralizing vaccine to HIV."
— Larry Corey, professor of medicine, University of Washington; former president, Fred Hutchinson Cancer Research Center

The background: The effects the HIV virus has on infected patients have been lessened via antiretroviral treatments, but production of a vaccine has proven elusive so far. Key reasons for this include the virus' outer structure, which allows it to hide from the immune system and because the virus mutates quickly.

What they did: The team based the study on its 2016 findings that pointed to vulnerability in the last 8 amino acids of the fusion peptide (FP), which is part of the spike on the surface of HIV used to enter human cells. They saw this as a target for a vaccine. (FPs are targeted in other types of viral vaccine trials, like those for dengue fever and influenza).

What they found:

  • The scientists developed a multitude of proteins called immunogens designed to activate immune response and tested them in mice to determine the most effective one. This first generation neutralized up to 10% of HIV-1 strains.
  • They paired this with a replica of the HIV spike in different combinations, and tested these in mice. One of these in the second generation neutralized up to 31% of viruses from the panel of 208 HIV strains.
  • Based on their analyses, the scientists adjusted the vaccine regimen and tested it in guinea pigs and monkeys. These tests also yielded antibodies that neutralized a substantial fraction of HIV strains.
  • Georgia Tomaras, director of research at Duke Human Vaccine Institute, says that the trial suggests that it's a "very promising target for HIV vaccine development."

What's next: After further development of the vaccine, NIAID hopes to begin a preliminary human trial in the second half of 2019.

"Our current results provide proof of principle that neutralizing antibodies to diverse strains of HIV can be induced. Future work is aimed at improving both the consistency and potency of the antibody... We look forward to developing a candidate vaccine that can be tested in human clinical studies."
— John Mascola, NIAID study author

Go deeper

Updated 8 mins ago - Politics & Policy

Bipartisan group reaches agreement on $1.2 trillion "hard" infrastructure bill

Sens. Mitt Romney (R-Utah) and Mark Warner (D-Va.) Photo: Bill Clark/CQ-Roll Call, Inc via Getty Images.

After weeks of long nights and endless Zoom calls, a bipartisan group of senators finally reached a deal on "the major issues" in their $1.2 trillion "hard" infrastructure package, GOP senators involved in the talks announced Wednesday.

Why it matters: It could be days before the group finishes writing the bill, but the Senate can begin debating the legislation in earnest now that they have resolved the outstanding issues. The bill needs 60 votes to advance in the Senate.

After walkout, Activision Blizzard employees vow to keep fighting

Bing Guan/Bloomberg via Getty Images

Organizers of a Wednesday walkout at Activision Blizzard, the gaming company behind "Call of Duty" and "World of Warcraft," are saying the demonstration "is not a one-time event that our leaders can ignore.”

Why it matters: Within the video game industry, sweeping promises for change are often followed by a handful of half-measures that fail to solve the systematic problems that caused them.

Scoop: Trump team blames conservative for loser endorsement

Donald Trump at rally in Texas. Photo: Dylan Hollingsworth/Bloomberg via Getty Images

Donald Trump's advisers are angry at David McIntosh, president of the conservative Club for Growth, for persuading the former president to endorse a losing candidate in the special election for Texas' 6th District.

Why it matters: Susan Wright's defeat Tuesday in a Republican runoff with Navy veteran Jake Ellzey dealt a blow to Trump's aura of invincibility as a Republican kingmaker. It's critical to his 2022 midterm endorsements and continued hold on the GOP.